For research use only. Not for therapeutic Use.
MOG peptide (35-55) is a fragment 35-55 of myelin oligodendrocyte glycoprotein (MOG) immunogenic peptide. MOG peptide (35-55) is specific to expanded CD4+ T cells, and induces experimental autoimmune encephalomyelitis (EAE) in animal model[1][2][3].
The expanded CD4+ T cells are largely specific for the myelin oligodendrocyte glycoprotein (MOG) immunogenic peptide 35-55 (MOG35-55), while clonally expanded CD8+ T cells were non-responsive to myelin peptides or proteins[1].
MOG peptide (35-55) (3 mg/mL for 0.1 mL; s.c.; single dose) results active induction of experimental autoimmune encephalomyelitis (EAE) in mice[2].
MOG peptide (35-55) (200 μg; s.c.; single dose) induces a increasing concentration of the eosinophil chemoattractant eotaxin-1 in the spinal cord in the course of EAE induced in C57BL/6 mice[3].
| Catalog Number | I042535 |
| CAS Number | 2022956-48-3 |
| Molecular Formula | C118H178N36O28S |
| Purity | ≥95% |
| Reference | [1]. Saligrama N, et al. Opposing T cell responses in experimental autoimmune encephalomyelitis. Nature. 2019 Aug;572(7770):481-487. [2]. Giralt M, et al. Active Induction of Experimental Autoimmune Encephalomyelitis (EAE) with MOG35-55 in the Mouse. Methods Mol Biol. 2018;1791:227-232. [3]. Ruppova K, et al. Eosinophils are dispensable for development of MOG35-55-induced experimental autoimmune encephalomyelitis in mice. Immunol Lett. 2021 Nov;239:72-76. |
